Related Experiment Video
Updated: Aug 10, 2025
07:24
Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
Published on: December 13, 2018
6.5K
Multi-hallmark long noncoding RNA maps reveal non-small cell lung cancer vulnerabilities
Roberta Esposito1,2,3, Taisia Polidori1,2,4, Dominik F Meise1,2
1Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Bern 3010 Switzerland.
Cell Genomics
|February 13, 2023
Summary
Researchers identified 80 oncogenic long noncoding RNAs (lncRNAs) critical for non-small cell lung cancer (NSCLC) progression. Two key lncRNAs, CHiLL1 and GCAWKR, show therapeutic potential by suppressing cancer hallmarks.
Area of Science:
- Genomics
- Cancer Biology
- Molecular Oncology
Background:
- Long noncoding RNAs (lncRNAs) are increasingly recognized for their roles in cancer, but their specific functions in driving cancer hallmarks are not fully understood.
- KRAS-mutant non-small cell lung cancer (NSCLC) presents a significant therapeutic challenge, with limited understanding of the lncRNAs contributing to its progression.
Purpose of the Study:
- To systematically identify and functionally characterize long noncoding RNAs (lncRNAs) that promote oncogenesis in KRAS-mutant non-small cell lung cancer (NSCLC).
- To prioritize lncRNAs with potential as therapeutic targets by assessing their roles in cancer hallmarks like proliferation, chemoresistance, and migration.
Main Methods:
- A pooled CRISPR deletion screen was performed on 831 lncRNAs in KRAS-mutant NSCLC cells to assess their impact on proliferation, chemoresistance, and migration.
- Integrative analysis of screening data was used to identify high-confidence oncogenic lncRNAs.
- Antisense oligonucleotide (ASO) screening was employed to validate the function of top candidate lncRNAs.
- Molecular phenotyping was conducted to elucidate the distinct transcriptional networks controlled by validated lncRNAs.
Main Results:
- The study identified 80 high-confidence oncogenic lncRNAs active in NSCLC, frequently amplified and overexpressed in tumors.
- Two lncRNAs, Cancer Hallmarks in Lung LncRNA 1 (CHiLL1) and GCAWKR, were shortlisted and demonstrated consistent suppression of cancer hallmarks upon knockdown in 2D and 3D tumor models.
- Functional characterization revealed that CHiLL1 and GCAWKR regulate distinct transcriptional networks to control cellular phenotypes.
Conclusions:
- This research uncovers a comprehensive landscape of functional lncRNAs in NSCLC, highlighting their critical roles in driving cancer progression.
- The identified oncogenic lncRNAs, particularly CHiLL1 and GCAWKR, represent potential therapeutic vulnerabilities and novel targets for NSCLC treatment.
- The study demonstrates the power of pooled CRISPR screening and integrative analysis for prioritizing disease-relevant lncRNAs.
Related Concept Videos
02:39lncRNA - Long Non-coding RNAs
8.7K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.7K
03:18Non-LTR Retrotransposons
11.6K
As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
11.6K